Global stable cell line development demand is anticipated to be valued at US$ 2.5 Billion in 2022, forecast to grow at a CAGR of 10.8%to be valued at US$ 7 Billion from 2022 to 2032.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 1 Billion |
| Expected Market Value (2022) | US$ 2.5 Billion |
| Anticipated Forecast Value (2032) | US$ 7 Billion |
| Projected Growth Rate (2022-2032) | 10.8% CAGR |
Stable cell line development is a service that covers the majority of cell cultures. It is primarily used in research and selective diagnosis, and the applications involved in stable cell line development include recombinant protein and antibody production, functional studies, drug screening, gene editing, assay development, and many other platforms.
The procedure entails transferring infected cells to a suitable medium for growth; stability testing is an important step in characterizing cell lines. It ensures the quality of the cell lines produced throughout the passage. The majority of stable cell line development is tailor made in response to institute requirements, ensuring a safe and effective investment. The majority of research activities involving stable cell line development are cancer causes, which makes this market more clinical.
According to the National Cancer Institute at the National Institutes of Health, there were approximately 8.2 million cancer deaths and 14 million new cases in 2012. As a result, efficient stable cell line development is required in modern research activities.
The market's expansion has been fueled by rising demand for cell line development in cancer research. Models have traditionally been used for the development of therapeutics in clinical research, and the advantages over stable cell line development result in a positive market outcome.
Companies working on such advancements completely transform the market by replacing traditional cell lines. Researchers, in addition to accepting disease mutations through stable cell line development, tend to focus on new drug development through such cell lines, which would aid in the expansion of the market for stable cell line development.
Companies in the market offer customized cell lines for selective research purposes; this practice allows customers to systematically route their desired end product. Most manufacturers offer price reductions to attract customers and build a loyal customer base. Efficiency and capacity are the two main criteria used to evaluate stable cell line development products, and the greater the product difference, the more market space it will occupy.
The market is influenced by the complexity of advanced stable cell line development procedures. Stable cell line development, on the other hand, being one of the first lines in clinical research, provides an open market with enormous potential to reach its peak.
The stable cell line development market will be hampered by high capital costs and high expenditure required for research and development capabilities. Complexities in the development of stable cell lines will complicate the market's growth rate even more. The absence of a favourable and adequate reimbursement scenario in developing and underdeveloped economies will also dampen market growth rates.
Greater China is expected to hold a stellar revenue share in the APEJ stable cell line development market in 2022, with an astronomical CAGR during the forecast period. Increased government funding and private initiatives for research and development programmes for stable cell line development can be attributed to growth.
Furthermore, the widespread acceptance of Chinese Hamster Ovary cells as the first stable mammalian cell for stable cell line development, as well as their widespread acceptance for culturing and manipulation for biopharmaceutical use, will boost market growth in the APEJ region.
According to Future Market Insights, The United States dominated the North American stable cell line development market in 2021, with a total market share of more than 90.8%, and is expected to continue experiencing rapid growth throughout the forecast period.
The increasing demand for monoclonal antibodies for the treatment of COVID-19 infected patients in the region is driving the growth of this market. Furthermore, the absence of non-revised patent rights for major biologics has resulted in the expansion of generic as well as novel stable cell line development processes, fueling sales of stable cell line development in the region.
Some of the major players in the global Stable Cell Line Development Market include GenScrip, Molecular Devices, and LLC. Thermo Fisher Scientific, ProteoGenix, Sino Biological Inc., OriGene Technologies, Inc., and Fusion Antibodies plc.
| Report Attribute | Details |
| Growth Rate | CAGR of 10.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Source:
By Application:
By Cell Lines:
By End Users:
By Region:
FMI projects the global Stable Cell Line Development market to expand at a 10.8% value CAGR by 2032
U.S is expected to be the most opportunistic Stable Cell Line Development market, accumulating 90.8% revenue in 2021
GenScrip, Molecular Devices, LLC. Thermo Fisher Scientific, ProteoGenix, and Sino Biological Inc., are some prominent stable cell line development manufacturers
Explore Similar Insights
Stable Cell Line Development Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
